Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.63 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333820 | 0.88 | HTR1A (0.71) | KCNH2SIGMAR1HTR1ASLC6A4 | |
| SCHEMBL1333250 | 0.88 | KCNH2 (0.71) | KCNH2TMEM97SIGMAR1 | |
| SCHEMBL1334223 | 0.86 | KCNH2 (0.66) | KCNH2TMEM97SIGMAR1 | |
| SCHEMBL2158157 | 0.86 | KCNH2 (0.63) | KCNH2TMEM97SIGMAR1HTR1ASLC6A4 | |
| SCHEMBL4194933 | 0.85 | KCNH2 (0.49) | KCNH2HTR1ASLC6A4 | |
| SCHEMBL1333955 | 0.85 | HRH3 (0.62) | KCNH2TMEM97SIGMAR1HTR1AHRH3 | |
| SCHEMBL1332018 | 0.84 | KCNH2 (0.64) | KCNH2TMEM97SIGMAR1HRH3 | |
| SCHEMBL1332075 | 0.82 | ABCB1 (0.61) | KCNH2TMEM97SIGMAR1HTR1ASLC6A4 | |
| SCHEMBL2157337 | 0.81 | KCNH2 (0.60) | KCNH2TMEM97SIGMAR1 | |
| SCHEMBL1334381 | 0.81 | KCNH2 (0.66) | KCNH2HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-2340835-A1 | Piperidine and piperazine derivatives | M's Science Corporation (JP) | 2011-07-06 | — | — | EP | disclosed |
| EP-1976525-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | AGY THERAPEUTICS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SUN CONNIE L | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SIGMAR1, OPRM1, OPRD1 | KCNH2 332/4885TMEM97 8/4885SIGMAR1 1/4885 |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | SIGMAR1, OPRM1, OPRD1 | KCNH2 360/4885TMEM97 7/4885SIGMAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.